Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India proposes to make compensation for trial-related injuries and registration of ethics panels mandatory

This article was originally published in Scrip

Executive Summary

The Indian government wants feedback on proposals to introduce mandatory requirements for compensating clinical trial subjects for trial-related injuries/deaths and for registering ethics committees with the licensing authority before they can review or approve a trial protocol.

You may also be interested in...



Beovu & Recarbrio Among Five Drugs On Track For EU-Wide Approval

Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.

EU Preserves Status Quo On Drugs Under Additional Monitoring

The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.

Singapore And Malaysia Test Joint Evaluation

A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.

Topics

UsernamePublicRestriction

Register

SC018417

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel